Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Study of ATR-002

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04385420
Recruitment Status : Completed
First Posted : May 12, 2020
Last Update Posted : May 13, 2020
Sponsor:
Collaborator:
SGS Life Sciences, a division of SGS Belgium NV
Information provided by (Responsible Party):
Atriva Therapeutics GmbH

Brief Summary:

This was a combination of a single ascending dose (SAD) study to evaluate the safety, tolerability, and PK of 3 oral doses of a MEK inhibitor and a multiple ascending dose (MAD) study of 3 oral doses of a MEK inhibitor.

Subjects were to be enrolled in 3 different cohorts in the SAD and 3 different cohorts in the MAD and were to be randomly (blinded) allocated to active treatment or placebo (each cohort consisted of 8 subjects receiving active treatment and 2 subjects receiving placebo).


Condition or disease Intervention/treatment Phase
Influenza Drug: ATR-002 MEK Inhibitor Drug: Placebo oral tablet Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

This was a combination of a single ascending dose (SAD) study to evaluate the safety, tolerability, and PK of 3 oral doses of a MEK inhibitor and a multiple ascending dose (MAD) study of 3 oral doses of a MEK inhibitor.

Subjects were to be enrolled in 3 different cohorts in the SAD and 3 different cohorts in the MAD and were to be randomly (blinded) allocated to active treatment or placebo (each cohort consisted of 8 subjects receiving active treatment and 2 subjects receiving placebo).

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:

Between each cohort, a blinded interim analysis of PK, safety and tolerability had to be performed. The available data was evaluated by the Investigator and sponsor in a Safety Review Committee (SRC) meeting.

Once a dose level was judged to be safe, the SRC determined the dose level for the next cohort considering a maximal increment of 400 mg compared to the previous cohort, and the next dose level could be administered to the next cohort.

Primary Purpose: Treatment
Official Title: Phase 1 Single Dose Escalation/Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of Ascending Doses of a MEK Inhibitor (ATR-002) Given for 7 Days in Healthy Subjects
Actual Study Start Date : April 24, 2019
Actual Primary Completion Date : August 26, 2019
Actual Study Completion Date : August 26, 2019

Arm Intervention/treatment
Experimental: ATR-002 100 mg (SAD)
100 mg ATR-002 once (morning)
Drug: ATR-002 MEK Inhibitor
Drug ATR-002 administered as film-coated tablet via oral route
Other Name: PD01842649

Experimental: ATR-002 300 mg (SAD)
300 mg ATR-002 once (morning)
Drug: ATR-002 MEK Inhibitor
Drug ATR-002 administered as film-coated tablet via oral route
Other Name: PD01842649

Experimental: ATR-002 600 mg (SAD)
600 mg ATR-002 once (morning)
Drug: ATR-002 MEK Inhibitor
Drug ATR-002 administered as film-coated tablet via oral route
Other Name: PD01842649

Experimental: ATR-002 900 mg (SAD)
900 mg ATR-002 once (morning)
Drug: ATR-002 MEK Inhibitor
Drug ATR-002 administered as film-coated tablet via oral route
Other Name: PD01842649

Placebo Comparator: Placebo (SAD)
Placebo once (morning)
Drug: Placebo oral tablet
Placebo film-coated tablet administered via oral route

Experimental: ATR-002 100 mg (MAD)
100 mg ATR-002 once daily (morning) for 7 days
Drug: ATR-002 MEK Inhibitor
Drug ATR-002 administered as film-coated tablet via oral route
Other Name: PD01842649

Experimental: ATR-002 300 mg (MAD)
300 mg ATR-002 once daily (morning) for 7 days
Drug: ATR-002 MEK Inhibitor
Drug ATR-002 administered as film-coated tablet via oral route
Other Name: PD01842649

Experimental: ATR-002 600 mg (MAD)
600 mg ATR-002 once daily (morning) for 7 days
Drug: ATR-002 MEK Inhibitor
Drug ATR-002 administered as film-coated tablet via oral route
Other Name: PD01842649

Placebo Comparator: Placebo (MAD)
Placebo once daily (morning) for 7 days
Drug: Placebo oral tablet
Placebo film-coated tablet administered via oral route




Primary Outcome Measures :
  1. Treatment-emergent adverse events (TEAE) - SAD [ Time Frame: Day 1- Day 5 ]
    TEAEs in SAD groups

  2. Treatment-emergent adverse events (TEAE) - MAD [ Time Frame: Day 1 - Day 11 ]
    TEAEs in MAD groups


Secondary Outcome Measures :
  1. Maximum plasma concentration - Cmax (SAD) [ Time Frame: Day 1- Day 5 ]
    Cmax in SAD groups

  2. Time to maximum plasma concentration tmax (SAD) [ Time Frame: Day 1- Day 5 ]
    Tmax in SAD groups

  3. Area under plasma concentration AUC0-t (SAD) [ Time Frame: Day 1- Day 5 ]
    AUC0-t in SAD groups

  4. Area under plasma concentration AUC0-inf (SAD) [ Time Frame: Day 1- Day 5 ]
    AUC0-inf in SAD groups

  5. Elimination half-life t1/2 (SAD) [ Time Frame: Day 1- Day 5 ]
    t1/2 in SAD groups

  6. Maximum plasma concentration - Cmax (MAD) [ Time Frame: Day 1 - Day 11 ]
    Cmax in MAD groups

  7. Time to maximum plasma concentration tmax (MAD) [ Time Frame: Day 1 - Day 11 ]
    Tmax in MAD groups

  8. Area under plasma concentration AUC0-t (MAD) [ Time Frame: Day 1 - Day 11 ]
    AUC0-t in MAD groups

  9. Area under plasma concentration AUC0-tau (MAD) [ Time Frame: Day 1 - Day 11 ]
    AUC0-tau in MAD groups

  10. Minimum plasma concentration Ctrough (MAD) [ Time Frame: Day 1 - Day 11 ]
    Ctrough in MAD groups

  11. Area under plasma concentration AUC0-inf (MAD) [ Time Frame: Day 1 - Day 11 ]
    AUC0-inf in MAD groups

  12. Elimination half-life t1/2 (MAD) [ Time Frame: Day 1 - Day 11 ]
    T1/2 in MAD groups

  13. Accumulation ratio Cmax (MAD) [ Time Frame: Day 1 - Day 11 ]
    Cmax Accumulation in MAD groups

  14. Accumulation ratio AUC0-tau (MAD) [ Time Frame: Day 1 - Day 11 ]
    AUC0-tau accumulation ratio in MAD groups

  15. Accumulation ratio Ctrough (MAD) [ Time Frame: Day 1 - Day 11 ]
    Ctrough accumulation ratio in MAD groups



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female, between 18 and 55 years old, extremes included;
  2. Weighed at least 50 kg and had a body mass index (BMI) within normal range: 18.0≤ BMI <31.0 kg/m2;
  3. In good physical and mental health as determined on the basis of medical history and general physical examination performed at screening;
  4. Haematology and chemistry parameters, pulse rate and/or blood pressure, and ECG within the reference range for the population studied, or showing no clinically relevant deviations, as judged by the Investigator;
  5. Negative urine test for selected drugs of abuse at screening and upon check-in at the clinical site; Note: Subjects could not consume poppy-seeds within 24h before screening and before each urine drug screening because this could falsify the results of the opiate urine drug test.
  6. Negative alcohol breath test at screening and upon check-in at the clinical site;
  7. Negative hepatitis panel (including hepatitis B surface antigen [HBsAg] and anti hepatitis C virus [HCV] antibodies) and negative human immunodeficiency virus (HIV) antibody screens;
  8. Female subjects had to be of non-childbearing potential, as follows:

    1. At least 1 year post-menopausal (amenorrhea >12 months in the absence of an alternative medical cause and follicle-stimulating hormone >30 mIU/mL in women not using hormonal contraception or hormonal replacement therapy) prior to screening;
    2. Surgically sterile (bilateral oophorectomy, hysterectomy, bilateral salpingectomy, or bilateral tubal ligation);
  9. To protect partners from possible exposure to study medication in semen, male subjects had to use a condom during the study, even if they had a vasectomy or their partner was not of childbearing potential.

    Note: medically acceptable methods of contraception that could be used by the partner included combined oral contraceptive, contraceptive vaginal ring, contraceptive injection, intrauterine device, and etonogestrel implant;

  10. Willing to adhere to the prohibitions and restrictions specified in the protocol (see Appendix 16.1.1);
  11. Ability to comprehend the nature of the study and any hazards of participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire study;
  12. Informed Consent Form (ICF) signed voluntarily before any study-related procedure was performed, indicating that the subject understood the purpose of and procedures required for the study and was willing to participate in the study.

Exclusion Criteria:

  1. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-study screening assessment that could interfere with the objectives of the study or the safety of the subject;
  2. Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the subject's participation in the study or make it unnecessarily hazardous;
  3. A condition that, in the opinion of the Investigator, could compromise the well being of the subject or course of the study, or prevent the subject from meeting or performing any study requirements;
  4. Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, cancer, or history of any psychotic mental illness;
  5. Respiratory tract infection within 4 weeks before the screening visit;
  6. History of surgery or medical intervention, or planned surgery or medical intervention, that could interfere with the objectives of the study or the safety of the subject;
  7. Presence or history of severe adverse reaction to any drug, or sensitivity to components of the study medication;
  8. Use of a prescription or over-the-counter medicine, with the exception of acetaminophen (paracetamol), during the 7 days (or 5 half-lives, whichever is longer) before the first dose of study medication;
  9. Participation in another clinical study of a new chemical entity, new device, or a prescription medicine within the 3 months before dosing, or participation within 5 half-lives of receiving an experimental drug (whichever is longer);
  10. Presence or history of drug or alcohol abuse, or intake of more than 21 units (14 units for women) of alcohol weekly;
  11. Use of a prohibited therapy;
  12. Current smoker; or ex-smokers who (a) gave up less than 1 year ago, or (b) who had a history of more than 10 pack-years; Pack-years = cigarettes per day x number of years smoked/20
  13. Blood pressure and heart rate at the screening examination outside the ranges 90 150 mmHg systolic, 40-90 mmHg diastolic; heart rate 40-100 bpm;
  14. Loss of more than 400 mL blood, e.g. as a blood donor, or donation of blood products, during the 3 months before the study;
  15. History of tuberculosis infection;
  16. Receipt of a living vaccine within the 3 months before dosing;
  17. Active or latent parasitic infection, visit to a country with a high prevalence of parasitic infections within 3 months before receiving study medication;
  18. Positive faecal blood test at screening;
  19. Employee of the Investigator or the Sponsor, who was directly involved in the study, or a first-degree relative of such person;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04385420


Locations
Layout table for location information
Belgium
SGS Life Sciences, Clinical Pharmacology Unit Antwerpen
Antwerp, Belgium, 2020
Sponsors and Collaborators
Atriva Therapeutics GmbH
SGS Life Sciences, a division of SGS Belgium NV
Investigators
Layout table for investigator information
Principal Investigator: Bram Volckaert, MD SGS Belgium NV
Layout table for additonal information
Responsible Party: Atriva Therapeutics GmbH
ClinicalTrials.gov Identifier: NCT04385420    
Other Study ID Numbers: ATR002-01
First Posted: May 12, 2020    Key Record Dates
Last Update Posted: May 13, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No